In collaboration with Merck, the intravenous formulation of Cardiome's lead molecule, vernakalant (IV), was granted marketing approval in September, 2010 in the European Union, Iceland and Norway under the trademark BRINAVESSTM for rapid conversion of recent onset AF to sinus rythm in adults. It continues to expand into new markets around the world. + READ MORE
20 February, 2014
Cardiome Announces C$30 Million Primary And Secondary Common Share Offering
19 February, 2014
Cardiome Announces Update In Commercialization Partnership For BRINAVESS™ In Select European Markets
Cardiome is a research-based biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the quality of life and health of patients. We strive to find innovative medicines that provide values to patients, physicians and healthcare systems.